{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:11:05Z","timestamp":1753891865774,"version":"3.41.2"},"reference-count":70,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T00:00:00Z","timestamp":1737417600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Breast cancer (BC) is the leading cause of cancer-related mortality among women. The backbone of first-line treatment in HR+\/HER2+ BC is dual anti-HER2 blockade combined with taxane chemotherapy. Although this regimen exhibits high rates of response and disease control in both HR+ and HR\u2212 cohorts, some patients could have intrinsic or develop acquired resistance to trastuzumab and\/or pertuzumab. Here, we achieved a near-complete response in HR+ <jats:italic>HER2<\/jats:italic>-amplified and overexpressing metastatic BC twice through molecular tumor board (MTB) discussions: initially, with trastuzumab deruxtecan (T-DXd) when HER2 IHC was positive, and, then, with neratinib plus fulvestrant plus paclitaxel when IHC was negative. Our case presents <jats:italic>GATA3<\/jats:italic> and <jats:italic>NOTCH2<\/jats:italic> mutations, <jats:italic>MCL1<\/jats:italic> and <jats:italic>CKS1B<\/jats:italic> amplifications, as well as <jats:italic>ERBB3\/KRAS<\/jats:italic> overexpression and ER signaling as potential new mechanisms of resistance to T-DXd. Furthermore, we demonstrated that triplet combination could induce a remarkable response in the T-DXd\u2013refractory setting, which could be explored in future clinical trials in HR+ and HER2-activated (by RNA or protein overexpression, amplification, and mutation) patients. Our case also highlights the importance of the MTBs to dynamically and reactively manage the course of disease and treatment on a per-patient basis.<\/jats:p>","DOI":"10.3389\/fonc.2024.1484750","type":"journal-article","created":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T08:38:51Z","timestamp":1737448731000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Case report: Near-complete response to neratinib-based treatment in HR-positive HER2-amplified metastatic breast cancer refractory to trastuzumab deruxtecan"],"prefix":"10.3389","volume":"14","author":[{"given":"\u00dcnal Metin","family":"Tokat","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashkan","family":"Adibi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esranur","family":"Ayd\u0131n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u015eevval Nur","family":"Bilgi\u00e7","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eyl\u00fcl","family":"\u00d6zg\u00fc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Onur","family":"Tutar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mutlu","family":"Demiray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,1,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.10528","article-title":"Breast cancer: Global patterns of incidence, mortality, and trends","volume-title":"J Clin Oncol.","author":"Sedeta","year":"2023"},{"key":"B3","doi-asserted-by":"publisher","first-page":"595","DOI":"10.5858\/arpa.2013-0566-CP","article-title":"Template for reporting results of biomarker testing of specimens from patients with carcinoma of the breast","volume":"138","author":"Fitzgibbons","year":"2014","journal-title":"Arch Pathol Lab Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"102529","DOI":"10.1016\/j.ctrv.2023.102529","article-title":"Optimizing treatment for HER2-positive HR-positive breast cancer","volume":"115","author":"Debien","year":"2023","journal-title":"Cancer Treat Rev"},{"key":"B5","doi-asserted-by":"publisher","first-page":"102761","DOI":"10.1016\/j.ctrv.2024.102761","article-title":"The evolving landscape of metastatic HER2-positive, hormone receptor-positive Breast Cancer","volume":"128","author":"Boscolo Bielo","year":"2024","journal-title":"Cancer Treat Rev"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.06.024","article-title":"Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication","volume":"32","author":"Miles","year":"2021","journal-title":"Ann Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30863-0","article-title":"Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study","volume":"21","author":"Swain","year":"2020","journal-title":"Lancet Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1914510","article-title":"Trastuzumab deruxtecan in previously treated HER2-positive breast cancer","volume":"382","author":"Modi","year":"2020","journal-title":"New Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00725-0","article-title":"Trastuzumab deruxtecan versus treatment of physician\u2019s choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial","volume":"401","author":"Andr\u00e9","year":"2023","journal-title":"Lancet"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2115022","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer","volume":"386","author":"Cort\u00e9s","year":"2022","journal-title":"New Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s40261-018-0719-0","article-title":"Safety and efficacy profile of neratinib: a systematic review and meta-analysis of 23 prospective clinical trials","volume":"39","author":"Tao","year":"2019","journal-title":"Clin Drug Invest"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00551-3","article-title":"Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"17","author":"Chan","year":"2016","journal-title":"Lancet Oncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.1200\/JCO.19.00858","article-title":"Safety and efficacy of T-DM1 plus neratinib in patients with metastatic HER2-positive breast cancer: NSABP foundation trial FB-10","volume":"37","author":"Abraham","year":"2019","journal-title":"J Clin Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.clbc.2018.12.011","article-title":"Neratinib in combination with trastuzumab for the treatment of patients with advanced HER2-positive breast cancer: a phase I\/II study","volume":"19","author":"Blackwell","year":"2019","journal-title":"Clin Breast Cancer"},{"key":"B15","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13058-019-1112-5","article-title":"Patterns of occurrence and implications of neratinib-associated diarrhea in patients with HER2-positive breast cancer: analyses from the randomized phase III ExteNET trial","volume":"21","author":"Mortimer","year":"2019","journal-title":"Breast Cancer Res"},{"key":"B16","doi-asserted-by":"publisher","first-page":"51","DOI":"10.2147\/CE.S217848","article-title":"Pertuzumab in the treatment of HER2-positive breast cancer: an evidence-based review of its safety, efficacy, and place in therapy","volume":"14","author":"Ishii","year":"2019","journal-title":"Core evidence"},{"key":"B17","doi-asserted-by":"publisher","first-page":"100343","DOI":"10.1016\/j.esmoop.2021.100343","article-title":"How we treat patients with metastatic HER2-positive breast cancer","volume":"7","author":"Nader-Marta","year":"2022","journal-title":"ESMO Open"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.1014","article-title":"Efficacy of tucatinib+ trastuzumab+ capecitabine (TTC) after trastuzumab-deruxtecan (T-DXd) exposure in Her2-positive metastatic breast cancer: A French multicentre retrospective study","volume":"41","author":"Frenel","year":"2023","journal-title":"Am Soc Clin Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1200\/PO.22.00604","article-title":"Comprehensive analysis of human epidermal growth factor receptor 2 through DNA, mRNA, and protein in diverse Malignancies","volume":"7","author":"Shayeb","year":"2023","journal-title":"JCO Precis Oncol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"100408","DOI":"10.1016\/j.modpat.2023.100408","article-title":"Correlation of HER2 protein level with mRNA level quantified by RNAscope in breast cancer","volume":"37","author":"Li","year":"2024","journal-title":"Modern Pathol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"5650","DOI":"10.3390\/cancers14225650","article-title":"HER2 mRNA levels, estrogen receptor activity and susceptibility to trastuzumab in primary breast cancer","volume":"14","author":"Triulzi","year":"2022","journal-title":"Cancers"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12071902","article-title":"ERBB2 mRNA expression and response to ado-trastuzumab emtansine (T-DM1) in HER2-positive breast cancer","volume":"12","author":"Griguolo","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02992-x","article-title":"Trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory biomarker analysis of the randomized, phase 2 DESTINY-Gastric01 trial","volume":"30","author":"Shitara","year":"2024","journal-title":"Nat Med"},{"key":"B24","doi-asserted-by":"publisher","first-page":"10213","DOI":"10.1038\/s41467-024-53223-3","article-title":"HER2-related biomarkers predict clinical outcomes with trastuzumab deruxtecan treatment in patients with HER2-expressing metastatic colorectal cancer: biomarker analyses of DESTINY-CRC01","volume":"15","author":"Siena","year":"2024","journal-title":"Nat Commun"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-10-1872","article-title":"Trastuzumab has preferential activity against breast cancers driven by HER2 homodimers","volume":"71","author":"Ghosh","year":"2011","journal-title":"Cancer Res"},{"key":"B26","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N Engl J Med"},{"key":"B27","first-page":"2110","article-title":"Trastuzumab aeruxtecan after endocrine therapy in metastatic breast cancer","volume-title":"N Engl J Med","author":"Bardia","year":"2024"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02478-2","article-title":"Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial","volume":"29","author":"Mosele","year":"2023","journal-title":"Nat Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103016","article-title":"7P Trastuzumab deruxtecan (T-DXd) for advanced breast cancer (ABC) patients (pts), regardless of HER2 status: A phase II study with biomarkers analysis (DAISY)-update analysis with longer follow-up","volume":"9","author":"Dieras","year":"2024","journal-title":"ESMO Open"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1200\/PO.23.00076","article-title":"Genomics of ERBB2-Positive breast cancer in young women before and after exposure to chemotherapy plus trastuzumab","volume":"7","author":"Lipsyc-Sharf","year":"2023","journal-title":"JCO Precis Oncol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.annonc.2023.01.009","article-title":"Genomic characterisation of hormone receptor-positive breast cancer arising in very young women","volume":"34","author":"Luen","year":"2023","journal-title":"Ann Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2016.03.038","article-title":"GATA3 mRNA expression, but not mutation, associates with longer progression-free survival in ER-positive breast cancer patients treated with first-line tamoxifen for recurrent disease","volume":"376","author":"Liu","year":"2016","journal-title":"Cancer Lett"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1101\/2020.01.30.926733","article-title":"The mutational landscape of the SCAN-B real-world primary breast cancer transcriptome","volume":"12","author":"Brueffer","year":"2020","journal-title":"EMBO Mol Med"},{"key":"B34","doi-asserted-by":"publisher","first-page":"5679","DOI":"10.1038\/s41467-020-19342-3","article-title":"Characterization of the genomic landscape and actionable mutations in Chinese breast cancers by clinical sequencing","volume":"11","author":"Lang","year":"2020","journal-title":"Nat Commun"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1006279","article-title":"Gain- and loss-of-Function mutations in the breast cancer gene GATA3 result in differential drug sensitivity","volume":"12","author":"Mair","year":"2016","journal-title":"PloS Genet"},{"key":"B36","doi-asserted-by":"publisher","first-page":"17795","DOI":"10.1038\/s41598-024-68788-8","article-title":"Association of GATA3 expression in triple-positive breast cancer with overall survival and immune cell infiltration","volume":"14","author":"Chen","year":"2024","journal-title":"Sci Rep"},{"key":"B37","doi-asserted-by":"publisher","first-page":"604","DOI":"10.3390\/diagnostics11040604","article-title":"GATA3 as an adjunct prognostic factor in breast cancer patients with less aggressive disease: A study with a review of the literature","volume":"11","author":"Querzoli","year":"2021","journal-title":"Diagnostics (Basel)"},{"key":"B38","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.1065","article-title":"Landscape of GATA3 mutations identified from circulating tumor DNA clinical testing and their impact on disease outcomes in estrogen receptor-positive (ER+) metastatic breast cancers treated with endocrine therapies","volume-title":"J Clin Oncol.","author":"Velimirovic","year":"2021"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.jamcollsurg.2004.12.025","article-title":"GATA-3 expression as a predictor of hormone response in breast cancer","volume":"200","author":"Parikh","year":"2005","journal-title":"J Am Coll Surg"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-1000","article-title":"Molecular profiling of aromatase inhibitor-treated postmenopausal breast tumors identifies immune-related correlates of resistance","volume":"19","author":"Dunbier","year":"2013","journal-title":"Clin Cancer Res"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1286910","article-title":"Successful management of bilateral orbital metastases from invasive lobular breast cancer with abemaciclib and letrozole: a case report and literature review","volume":"14","author":"Rodrigues Alves","year":"2024","journal-title":"Front Oncol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"R23","DOI":"10.1186\/bcr2249","article-title":"Association of GATA3, P53, Ki67 status and vascular peritumoral invasion are strongly prognostic in luminal breast cancer","volume":"11","author":"Jacquemier","year":"2009","journal-title":"Breast Cancer Res"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-3573","article-title":"Landscape of baseline and acquired genomic alterations in circulating tumor DNA with abemaciclib alone or with endocrine therapy in advanced breast cancer","volume":"30","author":"Goetz","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B44","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/s41523-024-00688-6","article-title":"GATA3 and markers of epithelial-mesenchymal transition predict long-term benefit from tamoxifen in ER-positive breast cancer","volume":"10","author":"Sandstrom","year":"2024","journal-title":"NPJ Breast Cancer"},{"key":"B45","doi-asserted-by":"publisher","first-page":"17335","DOI":"10.1038\/s41598-019-53856-1","article-title":"Pyrrothiogatain acts as an inhibitor of GATA family proteins and inhibits Th2 cell differentiation in vitro","volume":"9","author":"Nomura","year":"2019","journal-title":"Sci Rep"},{"key":"B46","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/s42003-022-03296-x","article-title":"GATA3 and MDM2 are synthetic lethal in estrogen receptor-positive breast cancers","volume":"5","author":"Bianco","year":"2022","journal-title":"Commun Biol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-1699","article-title":"et al: GATA-3-dependent Gene Transcription is Impaired upon HDAC Inhibition","volume":"30","author":"Geng","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2011.156","article-title":"A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer","volume":"104","author":"Munster","year":"2011","journal-title":"Br J Cancer"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1101\/gad.342287.120","article-title":"The many facets of Notch signaling in breast cancer: toward overcoming therapeutic resistance","volume":"34","author":"Nandi","year":"2020","journal-title":"Genes Dev"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1186\/s12885-022-10383-z","article-title":"Notch signaling pathway: a comprehensive prognostic and gene expression profile analysis in breast cancer","volume":"22","author":"Yousefi","year":"2022","journal-title":"BMC Cancer"},{"key":"B51","doi-asserted-by":"publisher","first-page":"602467","DOI":"10.1101\/2024.07.08.602467","article-title":"Targeting NOTCH2-JAG1 juxtacrine signaling reverses macrophage-mediated tumor resistance to taxol","author":"Yu","year":"2024","journal-title":"bioRxiv"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/bcr1278","article-title":"The expression of the ubiquitin ligase subunit Cks1 in human breast cancer","volume":"7","author":"Slotky","year":"2005","journal-title":"Breast Cancer Res"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1534\/genetics.116.190231","article-title":"A synthetic dosage lethal genetic interaction between CKS1B and PLK1 is conserved in yeast and human cancer cells","volume":"204","author":"Reid","year":"2016","journal-title":"Genetics"},{"key":"B54","doi-asserted-by":"publisher","first-page":"4204","DOI":"10.1038\/s41598-017-04147-0","article-title":"Dacomitinib, a pan-inhibitor of ErbB receptors, suppresses growth and invasive capacity of chemoresistant ovarian carcinoma cells","volume":"7","author":"Momeny","year":"2017","journal-title":"Sci Rep"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-017-0108-9","article-title":"Targeting PLK1 overcomes T-DM1 resistance via CDK1-dependent phosphorylation and inactivation of Bcl-2\/xL in HER2-positive breast cancer","volume":"37","author":"Saatci","year":"2018","journal-title":"Oncogene"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aam7049","article-title":"Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancer","volume":"9","author":"Merino","year":"2017","journal-title":"Sci Transl Med"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1717820115","article-title":"Coamplification of miR-4728 protects HER2-amplified breast cancers from targeted therapy","volume":"115","author":"Floros","year":"2018","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B58","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s10020-023-00736-0","article-title":"Neratinib for HER2-positive breast cancer with an overlooked option","volume":"29","author":"Guo","year":"2023","journal-title":"Mol Med"},{"key":"B59","doi-asserted-by":"publisher","first-page":"3138","DOI":"10.1200\/JCO.20.00147","article-title":"Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with\u2265 2 HER2-directed regimens: phase III NALA trial","volume":"38","author":"Saura","year":"2020","journal-title":"J Clin Oncol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2023.7221","article-title":"TIP24-198: A multi-center phase I trial of neratinib and fam-trastuzumab deruxtecan in advanced refractory gastric cancer patients","volume":"22","author":"Nakrani","year":"2024","journal-title":"J Natl Compr Cancer Network"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-0152","article-title":"NSABP B-41, a randomized neoadjuvant trial: Genes and signatures associated with pathologic complete response","volume":"26","author":"Swain","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B62","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.1038\/s41416-024-02665-z","article-title":"Neratinib could be effective as monotherapy or in combination with trastuzumab in HER2-low breast cancer cells and organoid models","volume":"130","author":"Arshad","year":"2024","journal-title":"Br J Cancer"},{"key":"B63","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.18632\/oncotarget.v4i10","article-title":"Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer","volume":"4","author":"Canonici","year":"2013","journal-title":"Oncotarget"},{"key":"B64","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.3390\/cancers15041130","article-title":"Resistance to antibody-drug conjugates targeting HER2 in breast cancer: molecular landscape and future challenges","volume":"15","author":"Guidi","year":"2023","journal-title":"Cancers"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.3824","article-title":"RNA sequencing to predict response to neoadjuvant anti-HER2 therapy: a secondary analysis of the NeoALTTO randomized clinical trial","volume":"3","author":"Fumagalli","year":"2017","journal-title":"JAMA Oncol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-023-02426-4","article-title":"Differential response of HER2-positive breast cancer to anti-HER2 therapy based on HER2 protein expression level","volume":"129","author":"Atallah","year":"2023","journal-title":"Br J Cancer"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.08.003","article-title":"Neratinib+ fulvestrant+ trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial","volume":"34","author":"Jhaveri","year":"2023","journal-title":"Ann Oncol"},{"key":"B68","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.1020","article-title":"Trastuzumab deruxtecan (T-DXd) vs treatment of physician\u2019s choice (TPC) in patients (pts) with HER2-low, hormone receptor-positive (HR+) unresectable and\/or metastatic breast cancer (mBC): Exploratory biomarker analysis of DESTINY-Breast04","volume-title":"J Clin Oncol.","author":"Modi","year":"2023"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00064-0","article-title":"Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): Primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial","volume":"25","author":"Smit","year":"2024","journal-title":"Lancet Oncol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.2004088","article-title":"Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal","volume":"6","author":"Gao","year":"2013","journal-title":"Sci Signaling"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1484750\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T09:29:14Z","timestamp":1737970154000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1484750\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,21]]},"references-count":70,"alternative-id":["10.3389\/fonc.2024.1484750"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2024.1484750","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2025,1,21]]},"article-number":"1484750"}}